MEET QPS AT AD/PD™ 2024; March 5-9, Lisbon, Portugal

Alzheimer's Disease In Vitro Models

Alzheimer’s disease (AD) is one of the most devastating neurodegenerative diseases. Aggregation of amyloid-beta peptide (Aβ) into cytotoxic oligomers and fibrills is one of the major hallmarks in AD. These pathological depositions in the brain are thought to be one of the main causes for the observed progressive cognitive decline in AD patients.

Interfering with Aβ aggregation is an inevitable strategy in the development of novel therapeutic approaches. Reliable in vitro models are needed, which are capable of showing direct effects of compounds on Aβ oligomer formation and thus, a beneficial impact on cell viability.

animal models

QPS Neuropharmacology is highly experienced in generating, characterizing, and maintaining transgenic disease models and using them for drug testing projects for more than 20 years.

behavioral testing

QPS Neuropharmacology provides a wide range of behavioral tests for various indications. Most tests are evaluated using rater-independent digital animal tracking systems.

histology services

QPS Neuropharmacology offers a full set of histology services ranging from collection of tissue samples to delivering study reports that contain all experimental procedures and their outcome.


QPS Neuropharmacology Department of Translational Medicine offers a selection of molecular biological methods for the investigation of various diseases. The unit supports in vitro and in vivo studies performed at QPS Austria.